Discover eight key AI biotech deals that have been made so far in 2025, spotlighting where industry leaders are betting big.

ONL Therapeutics announced the first patient has been randomized in its phase 2 GALAXY ( NCT06659445) trial evaluating ...

Xelafaslatide is an investigational first-in-class small molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across a range of retinal ...

Ebola is one of the nasty viruses that can hide in the body even after a patient recovers and tests negative. It can reemerge and trigger a new outbreak years later. How do they survive? And how can ...

MT-125, a dual small-molecule inhibitor, received FDA fast track designation for glioblastoma, facilitating expedited drug ...

Roche has dropped five Chugai candidates from its clinical pipeline, echoing actions the Japanese business took earlier this ...

What if you could taste an early flu infection? Chemists report a molecular sensor that, when placed on an infected tongue as a thin film or gum, will release thyme’s main flavor compound, thymol (ACS ...

Beijing Advanced Innovation Center for Soft Matter Science and Engineering and State Key Laboratory of Organic−Inorganic Composites, Beijing University of Chemical Technology, Beijing 100029, People’s ...

Researchers have designed a peptide that prevents the deadly misfolding of alpha-synuclein, the protein behind Parkinson’s and some dementias. In lab and animal tests, it stabilized the protein and ...